Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?

Gastroenterology. 2003 Jun;124(7):1988-90. doi: 10.1016/s0016-5085(03)00569-9.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibody Formation
  • Crohn Disease / drug therapy*
  • Gastrointestinal Agents / administration & dosage*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Infliximab
  • Time Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab